keyword
MENU ▼
Read by QxMD icon Read
search

Hodgkin's

keyword
https://www.readbyqxmd.com/read/29791291/additional-evidence-that-end-of-treatment-fluorodeoxyglucose-positron-emission-tomography-evaluation-is-necessary-in-advanced-hodgkin-lymphoma
#1
Charles Mesguich, Krimo Bouabdallah, Noël Milpied, Elif Hindié
No abstract text is available yet for this article.
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29791288/strikingly-heterogeneous-results-among-studies-on-interim-fluorodeoxyglucose-positron-emission-tomography-adapted-treatment-in-advanced-stage-hodgkin-lymphoma
#2
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
May 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29790693/hounsfield-units-from-unenhanced-18f-fdg-pet-ct-are-useful-in-evaluating-supradiaphragmatic-lymph-nodes-in-children-and-adolescents-with-classical-hodgkin-s-lymphoma
#3
Radosław Chaber, Mateusz Łasecki, Justyna Kwaśnicka, Kornelia Łach, Zbigniew Podgajny, Cyprian Olchowy, Urszula Zaleska-Dorobisz
BACKGROUND: The precise identification of the primarily-affected nodal regions in Hodgkin's lymphoma(HL) is essential in determining the stage of the disease and the intensity of chemotherapy and radiotherapy. OBJECTIVES: The aim of this study was to use the degree of X-ray attenuation (XRA) in Hounsfield units(HU) and the lymph node-to-muscle attenuation ratio (LN/M) in computed tomography (CT) unenhancedimaging, routinely performed with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET),to distinguish HL-affected supradiaphragmatic lymph nodes...
May 16, 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29790667/differences-in-cancer-survival-among-white-and-black-cancer-patients-by-presence-of-diabetes-mellitus-estimations-based-on-seer-medicare-linked-data-resource
#4
Clara Lam, Kathleen Cronin, Rachel Ballard, Angela Mariotto
Diabetes prevalence and racial health disparities in the diabetic population are increasing in the US. Population-based cancer-specific survival estimates for cancer patients with diabetes have not been assessed. The Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage provided data on cancer-specific deaths and diabetes prevalence among 14 separate cohorts representing 1 068 098 cancer patients ages 66 +  years diagnosed between 2000 and 2011 in 17 SEER areas. Cancer-specific survival estimates were calculated by diabetes status adjusted by age, stage, comorbidities, and cancer treatment, and stratified by cancer site and sex with whites without diabetes as the reference group...
May 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29788970/an-autopsy-case-of-peripheral-t-cell-lymphoma-occurring-in-a-postpartum-woman-a-unique-case-suggesting-changes-in-the-immunocharacteristics-of-lymphoma-cells-before-and-after-delivery
#5
Kenichi Mizutani, Sohsuke Yamada, Xin Guo, Chizuru Futatsuya, Motona Kumagai, Akihiro Shioya, Akane Aikawa, Satoko Nakada, Nozomu Kurose, Hiroshi Minato, Takayuki Nojima
BACKGROUND: The occurrence of malignant lymphoma after delivery is an extremely rare event. Although several cases of Hodgkin lymphoma and B cell lymphoma and a few cases of peripheral T cell lymphoma (PTCL) after delivery have been reported, there are no report of autopsy cases of PTCL in the puerperal period. CASE PRESENTATION: A 32-year-old Japanese woman with a past medical history of atopic dermatitis and bronchial asthma presented with generalized eruptions four days after the delivery of her first child; generalized skin induration and lymphadenopathy subsequently emerged...
May 22, 2018: Diagnostic Pathology
https://www.readbyqxmd.com/read/29787597/asymmetric-and-symmetric-dimethylarginines-and-mortality-in-patients-with-hematological-malignancies-a-prospective-study
#6
Angelika Chachaj, Jerzy Wiśniewski, Justyna Rybka, Aleksandra Butrym, Monika Biedroń, Małgorzata Krzystek-Korpacka, Mariusz Grzegorz Fleszar, Maciej Karczewski, Tomasz Wróbel, Grzegorz Mazur, Andrzej Gamian, Andrzej Szuba
The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1...
2018: PloS One
https://www.readbyqxmd.com/read/29786758/long-term-complete-remission-following-tandem-autologous-stem-cell-transplantation-and-consolidative-radiotherapy-for-refractory-mediastinal-gray-zone-lymphoma
#7
Koji Takaishi, Tomoya Muto, Naoya Mimura, Jun Takiguchi, Yuhei Nagao, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Shio Mitsukawa, Masahiro Takeuchi, Chikako Ohwada, Satoshi Ota, Tohru Iseki, Chiaki Nakaseko, Emiko Sakaida
Mediastinal gray zone lymphoma (MGZL) is a provisional entity with intermediate features between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma. Outcomes for patients with MGZL are reportedly poorer than those for patients with cHL or primary mediastinal large B-cell lymphoma. Additionally, no standard management guidelines for patients with MGZL are available, primarily due to its recent identification, rarity, and challenges in diagnosis. Although recent several studies have suggested dose-adjusted EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone, and rituximab) may improve outcomes in patients with MGZL, numerous patients still suffer from relapsed/refractory MGZL, and the optimal management for such patients remains uncertain...
May 21, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29785756/how-do-we-move-towards-a-personalised-approach-in-the-treatment-of-early-hodgkin-lymphoma
#8
EDITORIAL
Maja V Maraldo, Tim M Illidge
No abstract text is available yet for this article.
May 22, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29785310/a-challenging-case-of-kikuchi-fujimoto-disease-associated-with-systemic-lupus-erythematosus-and-review-of-the-literature
#9
Mihaela Găman, Ana-Maria Vlădăreanu, Camelia Dobrea, Minodora Onisâi, Cristina Marinescu, Irina Voican, Daniela Vasile, Horia Bumbea, Diana Cîşleanu
Kikuchi-Fujimoto disease (KFD) or histiocytic necrotizing lymphadenitis is a rare disease that is frequently underdiagnosed due to clinical features that are similar to those of non-Hodgkin lymphomas, systemic lupus erythematosus (SLE), or infectious reactive lymphadenopathy. An excisional biopsy is required. We report a young Caucasian female diagnosed with KFD with skin lesions, complicating with SLE. The clinical course, laboratory, and CT findings are described, as are histopathologic features, for a better recognition of this rare disorder in clinical practice...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29783621/-18-f-fdg-pet-ct-in-hodgkin-lymphoma-current-usefulness-and-perspectives
#10
REVIEW
Salim Kanoun, Cedric Rossi, Olivier Casasnovas
Functional imaging using 18-fluorodeoxyglycose ([18 F]FDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma. This imaging modality allows for a significant improvement in staging, increased sensitivity, which involves differentiating residual tumors from fibrosis during assessment, and highly impacts treatment decisions into new PET-driven strategies. This review presents the main scientific data concerning the current applications of [18 F]FDG-PET/CT in Hodgkin lymphoma at baseline, interim, and the end of treatment evaluation along with the main PET-driven trials for therapeutic decisions...
May 18, 2018: Cancers
https://www.readbyqxmd.com/read/29781323/targeting-the-b-cell-receptor-pathway-a-review-of-current-and-future-therapies-for-non-hodgkin-s-lymphoma
#11
Thomas D Rodgers, Patrick M Reagan
The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas Covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas...
May 20, 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29779620/evaluation-of-fine-needle-aspiration-cytology-in-the-diagnosis-of-cervical-lymph-node-lymphomas
#12
Yoldez Houcine, Emna Romdhane, Ahlem Blel, Meriem Ksentini, Raoudha Aloui, Rim Lahiani, Nadia Znaidi, Mamia Ben Salah, Soumaya Rammeh
PURPOSE: Surgical biopsy examination is the gold standard for the diagnosis of lymph node lymphomas. Fine-needle aspiration cytology (FNAC) is a quick and safe method in the management of cervical lymph nodes. Its value in confirming recurrent or residual lymphoma is well established. However, its role in the primary diagnosis of lymph node lymphoma remains controversial. The aim of this study was to assess, in our experience, the reliability of FNAC in the diagnosis of cervical lymph node lymphomas...
April 28, 2018: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/29779412/primary-gastric-lymphoma-epidemiology-clinical-diagnosis-and-treatment
#13
Luis Miguel Juárez-Salcedo, Lubomir Sokol, Julio C Chavez, Samir Dalia
Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma and represents a wide spectrum of disease, ranging from indolent low-grade marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma to aggressive diffuse large B-cell lymphoma. The PGL is a relatively rare cancer and easily misdiagnosed due to its unspecific symptoms of the digestive tract. The medical literature and ongoing clinical trials were reviewed on the clinical presentation, diagnosis, prognosis, prevention, and treatment of PGL...
January 2018: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/29779330/-tolerance-and-pharmacodynamics-phase-%C3%A2-clinical-trial-study-of-chimeric-anti-cd20-monoclonal-antibody-ibi301-in-chinese-patients-with-cd20-positive-non-hodgkin-s-lymphoma
#14
B Jiang, J Y Qi, M Y Sun, Z J Li, W Liu, L J Liu, F K Zhang, L G Qiu
Objective: To evaluate the tolerance and safety of a human-mouse chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients achieved objective response with CD20(+) B-cell non-Hodgkin's lymphoma (NHL). Methods: Nine patients with CD20(+) B-cell NHL received dose-escalating IBI301 infusions (250 mg/m(2), n =3; 375 mg/m(2), n =3; 500 mg/m(2), n =3, respectively). The data of all patients were collected for safety analyses. The median exposures of 125 mg/m(2), 375 mg/m(2), 500 mg/m(2) dose groups were 243, 690 and 980 mg, respectively...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29779211/cutaneous-sarcoidosis-a-new-subset-in-the-spectrum-of-paraneoplastic-dermatoses
#15
M El-Khalawany, A Mosbeh, S Aboeldahab, S Ali
BACKGROUND: Sarcoidosis is a well-described disease that can be associated with various malignancies; however, this correlation is still not fully clarified. AIM: To determine the clinical and histological features, demographic characteristics, and prognosis of patients diagnosed with paraneoplastic sarcoidosis (PS). METHODS: This observational cohort prospective study included all patients diagnosed as cutaneous sarcoidosis. All patients were monitored for therapeutic response, prognosis, and any associated diseases or malignancies...
May 20, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29779010/low-mir200b-5p-levels-in-minor-salivary-glands-a-novel-molecular-marker-predicting-lymphoma-development-in-patients-with-sj%C3%A3-gren-s-syndrome
#16
Efstathia K Kapsogeorgou, Aristea Papageorgiou, Athanase D Protogerou, Michael Voulgarelis, Athanasios G Tzioufas
OBJECTIVES: Development of non-Hodgkin's lymphoma (NHL) is the major adverse outcome of Sjögren's syndrome (SS) affecting both morbidity and mortality. Preliminary evidence suggested that, although not deregulated compared with sicca controls, miR200b-5p levels are decreased in the minor salivary glands (MSGs) of SS patients with NHL. The aim of the current study was to evaluate the MSG expression of miR200b-5p in SS-associated NHLs and its potential predictive value for the identification of patients with SS susceptible to develop NHL...
May 19, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29778492/tanovea%C3%A2-for-the-treatment-of-lymphoma-in-dogs
#17
REVIEW
Erik De Clercq
Tanovea® (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or "double" prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs. Tanovea has been demonstrated to be effective against non-Hodgkin's lymphoma (NHL) in dogs, as well as canine cutaneous T-cell lymphoma, spontaneous canine multiple myeloma, naïve canine multicentric lymphoma and relapsed canine B-cell lymphoma...
May 17, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29775689/biomarkers-for-checkpoint-inhibition-in-hematologic-malignancies
#18
REVIEW
Djordje Atanackovic, Tim Luetkens
In the past few years we have seen remarkable paradigm shifts in the treatment of many solid tumors due to the introduction of inhibitors targeting immune checkpoints such as PD-1/PD-L1 and CTLA-4. Recent results indicate that checkpoint inhibition also represents a very promising approach for certain types of hematologic malignancies. Unfortunately, treatment with checkpoint inhibitors is also associated with substantial toxicities and high costs and only a subset of patients appears to derive clinical benefit from these treatments...
May 15, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29774169/phase-2-study-of-everolimus-for-relapsed-or-refractory-classical-hodgkin-lymphoma
#19
Patrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Background: The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-free survival (PFS). Novel therapies are required for patients refractory to chemotherapy and AHSCT. The mammalian target of rapamycin inhibitor everolimus has shown preliminary activity in preclinical models of HL and promising efficacy in patients with relapsed or refractory HL...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29774105/pre-clinical-activity-of-targeting-the-pi3k-akt-mtor-pathway-in-burkitt-lymphoma
#20
Maria Bhatti, Thomas Ippolito, Cory Mavis, Juan Gu, Mitchell S Cairo, Megan S Lim, Francisco Hernandez-Ilizaliturri, Matthew J Barth
Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been implicated in Burkitt lymphomagenesis and increased PI3K/AKT activation has been associated with worse outcomes in adults with aggressive B-cell non-Hodgkin lymphoma (B-NHL). Inhibitors of the PI3K/AKT pathway have been approved for the treatment of refractory indolent B-NHL and continue to be investigated for treatment of aggressive B-NHLs...
April 24, 2018: Oncotarget
keyword
keyword
48649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"